| Dear Fellow Skeptic, There's a simple, and maybe inevitable, way to make big money – at the expense of the Chinese government. In 2018, a small American biotech firm stunned the world when they showed they could "rewrite humans" to eliminate risk of disease. That's because this radical breakthrough will not just change how we treat diseases... It will determine which country is going to lead the future of medicine for the next 50 years – the United States or China. The stakes couldn't be higher... National Defense Magazine says the breakthrough has "China is investing billions to make itself a world leader in this." The MIT Technology Review says the breakthrough has "world-shaping potential." The U.S. Director of National Security says the breakthrough has "far-reaching economic and national security implications." That's the real reason President Trump signed "Executive Order 13771" just ten days after taking office. For us to beat China, he had to reduce regulations at the FDA first. The commercial value of the patent is astronomical. Investor's Business Daily estimates it's worth $75 billion. That means China, and the rest of the world, has to pay a license fee to use this new breakthrough. And a tiny American company owns the patent on this historic treatment. Its current market capitalization is just $1 billion. But analysts Keith Speight thinks it will be worth twice what Facebook is worth or $1 Trillion. That would be enough to turn every $1,000 into $1,000,000 (or more) >>> Sincerely, Josh Kaplan |
This email was sent to phanphuongthanh89.822152@blogger.com by Investiv, LLC
Forward to a friend | Unsubscribe or Mange which emails you get from TradersPro
Investing is Inherently Risky
There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.
Hypothetical Results Are Reported
Results and examples used in the Company's advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage.
The Company's simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading.
Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company's software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.
Offers Disinterested Commentary and Analysis
The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one's own recommendations.
The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company's principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase.
Disclaimers, Terms & Conditions | Privacy Policy
Copyright © 2019
No comments:
Post a Comment